Form 4: Insider Sells Shares at MapLight Therapeutics

Jonathan Gillis, CAAO and PAO of MapLight Therapeutics, Inc., reported the sale of company stock totaling over 120,000 shares between April 27-28, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Jonathan Gillis, identified as CAAO and PAO of MapLight Therapeutics, Inc., has reported transactions involving the sale of company stock.
• These sales occurred on April 27, 2026, and April 28, 2026.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted by Mr. Gillis on December 26, 2025.
• A total of 122,066 shares of voting common stock were sold across multiple transactions.
• The weighted average sale prices ranged from $28.27 to $30.86 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant volume of insider selling, even though it was conducted under a pre-planned Rule 10b5-1 trading plan.

Negatives

• Insider selling activity, particularly in significant volumes, can sometimes be interpreted negatively by the market, potentially signaling a lack of confidence or a belief that the stock is fully valued.
• The sales represent a reduction in direct beneficial ownership by a key executive.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of these sales under a pre-arranged Rule 10b5-1 plan is a common practice to avoid accusations of insider trading, providing a degree of insulation for the executive and the company.

Stakeholder Impact

• Shareholders may view the significant insider selling with caution, potentially leading to short-term downward pressure on the stock price, despite the Rule 10b5-1 plan.
• Employees holding stock options or grants may be affected by any perceived negative sentiment resulting from insider sales.
• Creditors and suppliers are unlikely to be directly impacted by this specific filing.

Key Dates

Recommendation

The filing reports insider sales executed under a Rule 10b5-1 plan, which is a standard procedure. While significant selling by an executive can be a concern, the pre-planned nature mitigates concerns about insider trading. Without further context on the company's financial health or future prospects, a 'hold' recommendation is prudent, advising investors to monitor future disclosures and company performance.

Keywords

Form 4, Insider Trading, Stock Sale, Rule 10b5-1, MapLight Therapeutics, Jonathan Gillis, Beneficial Ownership, Securities Exchange Act